Evidence map›Paper›PMID 39048814›Full record

ArticleCellular and molecular life sciences : CMLS2024

CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A.

Feifei Guo, Nawen Du, Xue Wen, Zhaozhi Li, Yantong Guo, Lei Zhou, Andrew R Hoffman, Lingyu Li, Ji-Fan Hu, Jiuwei Cui

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Feifei GuoCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
Nawen DuCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
Xue WenCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
Zhaozhi LiCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
Yantong GuoCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
Lei ZhouCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
Andrew R HoffmanStanford University School of Medicine, VA Palo Alto Health Care System, Palo Alto, CA, 94304, USA.
Lingyu LiCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China. lilingyu@jlu.edu.cn.
Ji-Fan HuCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China. jifan@stanford.edu.ORCID http://orcid.org/0000-0002-2174-0361
Jiuwei CuiCancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China. cuijw@jlu.edu.cn.

Funding

The Role of Long Noncoding RNAs in CancerI01BX002905 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HOFFMAN, ANDREW R · 2016 to 2023
–
BLRD VA I01 BX002905California Institute of Regenerative Medicine (CIRM) grant RT2-01942Jilin Provincial Development and Reform Commission 2021C10Jilin Provincial Finance Department JLSWSRCZX2020-023Jilin Provincial Finance Department JLSWSRCZX2020-100Jilin Provincial Health Commission 2016Q035the Biomedical Research Service of the Department of Veterans Affairs BX002905the Innovative Program of National Natural Science Foundation of China 82050003the National Key R&D Program of China 2018YFA0106902the National Key R&D Program of China 2020YFA0707704the National Natural Science Foundation of China 31871297the National Natural Science Foundation of China 32000431the National Natural Science Foundation of China 81874052the National Natural Science Foundation of China 82172690
6 · The paper itself

Abstract

Natural killer cells (NK) are the "professional killer" of tumors and play a crucial role in anti-tumor immunotherapy. NK cell desensitization is a key mechanism of tumor immune escape. Dysregulated NKG2D-NKG2DL signaling is a primary driver of this desensitization process. However, the factors that regulate NK cell desensitization remain largely uncharacterized. Here, we present the first report that circular RNA circARAP2 (hsa_circ_0069396) is involved in the soluble MICA (sMICA)-induced NKG2D endocytosis in the NK cell desensitization model. CircARAP2 was upregulated during NK cell desensitization and the loss of circARAP2 alleviated NKG2D endocytosis and NK cell desensitization. Using Chromatin isolation by RNA purification (ChIRP) and RNA pull-down approaches, we identified that RAB5A, a molecular marker of early endosomes, was its downstream target. Notably, transcription factor CTCF was an intermediate functional partner of circARAP2. Mechanistically, we discovered that circARAP2 interacted with CTCF and inhibited the recruitment of CTCF-Polycomb Repressive Complex 2 (PRC2) to the promoter region of RAB5A, thereby erasing histone H3K27 and H3K9 methylation suppression to enhance RAB5A transcription. These data demonstrate that inhibition of circARAP2 effectively alleviates sMICA-induced NKG2D endocytosis and NK cell desensitization, providing a novel target for therapeutic intervention in tumor immune evasion.

Indexed as

CCCTC-Binding FactorHistocompatibility Antigens Class IKiller Cells, Naturalrab5 GTP-Binding ProteinsRNA, CircularAnimalsEndocytosisEndosomesHumansMiceNK Cell Lectin-Like Receptor Subfamily KCCCTC-Binding FactorCTCF protein, humanHistocompatibility Antigens Class IKLRK1 protein, humanMHC class I-related chain ANK Cell Lectin-Like Receptor Subfamily KRAB5C protein, humanrab5 GTP-Binding ProteinsRNA, CircularcircRNAEndocytosisHistone methylationNK cell desensitizationNKG2DsMICA

Identifiers

PMID39048814
PMCPMC11335232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.